146 related articles for article (PubMed ID: 36205882)
1. Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy.
Kubota T; Tsukimura T; Shiga T; Togawa T; Sakuraba H
CEN Case Rep; 2023 May; 12(2):171-175. PubMed ID: 36205882
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
CEN Case Rep; 2023 Dec; ():. PubMed ID: 38135868
[TBL] [Abstract][Full Text] [Related]
4. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
5. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
7. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
8. Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
Lenders M; Brand E
Front Immunol; 2022; 13():1024963. PubMed ID: 36569886
[TBL] [Abstract][Full Text] [Related]
9. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
10. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
11. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
13. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
14. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
15. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
16. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
18. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
19. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
20. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]